全文获取类型
收费全文 | 3798篇 |
免费 | 330篇 |
国内免费 | 206篇 |
专业分类
耳鼻咽喉 | 53篇 |
儿科学 | 91篇 |
妇产科学 | 104篇 |
基础医学 | 291篇 |
口腔科学 | 46篇 |
临床医学 | 387篇 |
内科学 | 449篇 |
皮肤病学 | 52篇 |
神经病学 | 102篇 |
特种医学 | 208篇 |
外科学 | 347篇 |
综合类 | 762篇 |
预防医学 | 325篇 |
眼科学 | 45篇 |
药学 | 435篇 |
8篇 | |
中国医学 | 421篇 |
肿瘤学 | 208篇 |
出版年
2024年 | 21篇 |
2023年 | 47篇 |
2022年 | 87篇 |
2021年 | 132篇 |
2020年 | 113篇 |
2019年 | 57篇 |
2018年 | 90篇 |
2017年 | 80篇 |
2016年 | 76篇 |
2015年 | 151篇 |
2014年 | 174篇 |
2013年 | 205篇 |
2012年 | 301篇 |
2011年 | 308篇 |
2010年 | 237篇 |
2009年 | 243篇 |
2008年 | 222篇 |
2007年 | 247篇 |
2006年 | 203篇 |
2005年 | 130篇 |
2004年 | 94篇 |
2003年 | 94篇 |
2002年 | 87篇 |
2001年 | 65篇 |
2000年 | 30篇 |
1999年 | 13篇 |
1998年 | 33篇 |
1997年 | 32篇 |
1996年 | 28篇 |
1995年 | 36篇 |
1994年 | 21篇 |
1993年 | 30篇 |
1991年 | 12篇 |
1990年 | 7篇 |
1989年 | 13篇 |
1988年 | 10篇 |
1987年 | 10篇 |
1986年 | 11篇 |
1985年 | 11篇 |
1984年 | 9篇 |
1983年 | 10篇 |
1982年 | 7篇 |
1980年 | 6篇 |
1959年 | 49篇 |
1958年 | 103篇 |
1957年 | 107篇 |
1956年 | 79篇 |
1955年 | 82篇 |
1954年 | 67篇 |
1949年 | 10篇 |
排序方式: 共有4334条查询结果,搜索用时 0 毫秒
1.
2.
3.
4.
We report the case of a 26-year-old man affected by a symmetrical keratoderma localized to the interdigital spaces of the fingers. No occupational, traumatic, or irritant factors were discovered. Clinical and histological features were consistent with the diagnosis of symmetrical interdigital hyperkeratosis, a sporadic disorder described by Frei in 1926. We believe this condition to be less rare than the few cases reported in the literature would suggest. 相似文献
5.
6.
7.
目的 探讨上皮型钙粘蛋白 (E cadherin ,E cad)在子宫内膜癌中的表达意义。方法 采用免疫组织化学方法检测 16例子宫内膜癌及 10例子宫肌瘤、卵巢囊肿患者 (对照组 )的E cad表达。结果 子宫内膜癌患者的E cad表达阳性率较对照组显著增高 (P <0 .0 5 )。子宫内膜癌E cad表达水平 :①与临床分期相关 ,临床早期表达显著高于晚期 (P <0 .0 5 ) ;②与肿瘤细胞分化程度相关 ,分化越差 ,表达越低 (P <0 .0 5 ) ;③与子宫肌层浸润深度成反比 ,浸润肌层越深表达越低 (P <0 .0 5 )。结论 E cad在子宫内膜癌的侵袭转移中发挥重要的作用 ,它的丢失是癌细胞发生侵袭性生长过程中的关键环节 相似文献
8.
Suppression of human ovarian carcinoma metastasis by the metastasis-suppressor gene, BRMS1 总被引:7,自引:0,他引:7
Metastasis-suppressor genes, by definition, suppress metastasis without affecting tumorigenicity and, hence, present attractive targets as prognostic or therapeutic markers. BRMS1 (breast cancer metastasis suppressor) has recently been identified as a metastasis-suppressor gene for human breast cancer and melanoma. Expression of BRMS1 messenger RNA (mRNA) in multitissue including normal prostate, ovarian, testis, and colon has been detected by northern blot analysis. We hypothesize that the role of BRMS1 in tumor progression may not be limited to breast cancer and melanoma. We previously found that BRMS1 mRNA levels in primary ovarian epithelial carcinomas were significantly lower than that in normal ovarian and benign tumors (P < 0.05), and statistical analysis of BRMS1 mRNA levels revealed that BRMS1 mRNA levels were significantly higher in early tumor stages (I, II) compared with advanced tumor stages (III, IV) in which lymph node or distant metastases were present (P < 0.01). Our data showed that reduced BRMS1 mRNA seems to influence ovarian carcinoma metastatic ability. Therefore, we transfected BRMS1 plasmid into highly malignant ovarian carcinoma cell line, HO-8910PM, and examined cell biologic behaviors including proliferation, adhesion, invasion, and metastasis in vitro and in vivo. BRMS1 expression did not alter the proliferation of HO-8910PM cells in vitro and primary tumor formation in vivo. But, BRMS1 expression significantly suppressed the cell adhesion to extracellular matrix components and in vitro cell invasion in BRMS1-transfected HO-8910PM cells compared to parental HO-8910PM and vector-only transfectants (HO-8910PM-vect). Furthermore, motility of BRMS1 transfectants was inhibited. lung colony formation of intravenously injected BRMS1 transfectants in nude mice was significantly reduced. Also, BRMS1 transfectants form significantly less metastatic to organs of peritoneal cavity in orthotopically implanted ovarian tumor nude models. We further discovered that BRMS1 expression did downregulate expression of an actin-bundling protein associated with cell motility -fascin, which perhaps is the mechanism underlying BRMS1 suppression of metastasis. These data suggested that in addition to its already described role in breast cancer and melanoma, BRMS1 functions as a metastasis-suppressor gene in ovarian carcinoma by modifying several metastatic-associated phenotypes, offering a new target for therapeutic intervention. 相似文献
9.
10.
目的:探讨颅内动脉狭窄血管内球囊支架成形术的可行性、安全性及其疗效。方法:17例患者术前3天给予阿司匹林300mg/天和噻氯吡啶250mg/天,6F(Envoy)导引导管放置到颈内动脉远段或椎动脉近颅底段,造影获得工作位,评价血管狭窄程度:狭窄率=(1-狭窄处管径/狭窄远端管径)×100%,微导丝在路途导引下通过颅内动脉狭窄段,向远端直至P2或M2段,确保足够的支撑力。选择支架大小的依据为狭窄远端正常血管的直径,导丝引导下支架通过狭窄部位,造影确定支架位置正确,充盈球囊至5~6大气压,支架释放后造影确认展开良好,回撤球囊,无并发症,操作完毕。随访3~10月。结果:17例患者颅内动脉狭窄处植入支架,技术成功100%,造影显示狭窄由术前(78.3±12.9)%降至术后(6.8±7.3)%,狭窄的动脉管径恢复,短期随访(3~10个月)显示很好临床效果。术中出现一例蛛网膜下腔少量出血(SAH),对症治疗痊愈。6例随访造影未见血管再狭窄。结论:颅内动脉狭窄支架植入增加血管内径,改善血流量,减轻临床症状,是一种安全、可行有效的治疗方法。 相似文献